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Management of Septic Shock
This interactive feature addresses the approach to a clinical issue. A case vignette is followed by specific options, neither of which 
can be considered either correct or incorrect. In short essays, experts in the field then argue for each of the options. Readers can 
participate in forming community opinion by choosing one of the options and, if they like, providing their reasons.
C ase Vignet te
A Woman with Septic Shock
Rebecca E. Berger, M.D.
Ms. Jones is a 65-year-old woman with a history 
of hypertension who presents to the emergency 
department with a 3-day history of chills and 
dysuria. The only medication she is taking is 
amlodipine, at a dose of 10 mg daily; she had 
had normal electrolyte levels and renal function 
at a routine visit 6 weeks earlier. On arrival at the 
emergency department, she reports feeling dizzy.
She is 165 cm (65 in.) tall and weighs 70 kg 
(154 lb). Her temperature is 38.6°C (101.5°F), 
heart rate 125 beats per minute, blood pressure 
85/55 mm Hg (mean arterial pressure, 65 mm Hg), 
respiratory rate 28 breaths per minute, and oxy-
gen saturation as measured by pulse oximetry 
94% while she is breathing ambient air. A physi-
cal examination reveals dry mucous membranes; 
undetectable jugular venous pulsation; tachycar-
dia without gallops, rubs, or murmurs; clear 
lungs; and warm extremities. She has tenderness 
on palpation of her suprapubic region. You begin 
intravenous administration of a bolus of crystal-
loid solution.
Laboratory testing shows a creatinine level of 
1.8 mg per deciliter (159 μmol per liter) (normal 
range, 0.5 to 1.1 mg per deciliter [44 to 97 μmol 
per liter]), blood urea nitrogen 76 mg per deciliter 
(27 mmol per liter) (normal range, 7 to 20 mg per 
deciliter [2 to 7 mmol per liter]), lactate 5.0 mmol 
per liter (normal value, <2.0), anion gap 25 mmol 
per liter (normal range, 8 to 15), white-cell count 
20,000 per cubic millimeter (normal range, 4500 
to 11,000), and hemoglobin 9.0 g per deciliter 
(normal range, 12.0 to 15.5). Urinalysis shows 
3+ leukocyte esterase, more than 100 white cells 
per high-power field, and abundant bacteria.
You make a presumptive diagnosis of sepsis 
from a urinary source and begin treatment with 
intravenous antibiotics to target likely urinary 
pathogens. Ultrasonography of the kidneys and 
bladder reveals no hydronephrosis or evidence of 
obstruction.
After administration of 2100 ml of crystalloid 
fluid (30 ml per kilogram of body weight), the 
patient’s jugular venous pressure is 8 cm of water, 
but her systemic arterial pressure has decreased to 
80/50 mm Hg (mean arterial pressure, 60 mm Hg). 
During the 3 hours that she has been in the 
emergency department, she has produced 20 ml 
of urine, as measured through a Foley catheter 
that was placed on her arrival.
You place a central venous catheter and initi-
ate a norepinephrine infusion, which you adjust 
with a goal of raising her mean arterial pressure 
to 65 to 70 mm Hg. She is transferred to the 
intensive care unit (ICU); on arrival in the ICU, 
her mean arterial pressure is 65 mm Hg while 
she is receiving 40 μg of norepinephrine per 
minute, and her heart rate is 100 beats per min-
ute. A chest radiograph shows early evidence of 
acute lung injury and good central catheter place-
ment. Her arterial oxygen saturation is 100% 
while she is receiving 4 liters of oxygen through 
a nasal cannula.
You are aware that there are two main ap-
proaches to the management of septic shock in a 
patient such as Ms. Jones. One approach involves 
serial measurement of central venous pressure, 
central venous oxygen saturation (Scvo2), and 
hemoglobin, and following the early, goal- 
directed therapy (EGDT) protocol, in which speci-
fied targets are used for the initiation of inotro-
pic agents or transfusion of red cells.1 For 
example, if the central venous pressure is less 
than 8 mm Hg, additional fluid resuscitation is 
administered; if the Scvo2 is less than 70%, the 
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patient receives a transfusion of red cells until a 
hematocrit goal of at least 30% is reached, and 
if the Scvo2 remains less than 70%, inotropic 
support is initiated.
The second approach involves continuing in-
travenous administration of antibiotics and vaso-
pressors, guided by clinical signs including blood 
pressure and urine output, without serial central 
venous pressure monitoring, serial Scvo2 moni-
toring, transfusion of red cells, or administra-
tion of inotropic agents. You are undecided 
about which of these approaches would maxi-
mize the chance of survival for your patient with 
septic shock.
Treatment Op tions
Which of the following treatment strategies 
should you pursue for this patient?
1. Follow the EGDT protocol.
2. Monitor the patient and administer treatment 
on the basis of clinical signs.
To aid in your decision making, each of these 
approaches is defended in a short essay by an 
expert in the field. Given your knowledge of the 
patient and the points made by the experts, which 
option would you choose? Make your choice, vote, 
and offer your comments at NEJM.org.
Op tion 1
Follow the EGDT Protocol
Emanuel Rivers, M.D.
Ms. Jones has been admitted to the ICU with 
septic shock and is receiving vasopressors to ele-
vate her mean arterial pressure. Shortly after her 
arrival, her condition deteriorates, and intubation 
and mechanical ventilation are initiated because 
of acute lung injury. The increased lactate level 
and low Scvo2 indicate inadequacy of systemic 
oxygen delivery (hypoxia, anemia, or decreased 
cardiac output) to meet demands (increased 
work of breathing).
The EGDT protocol expanded the landscape 
of sepsis management outside the ICU with a 
series of steps.1 Step one is early detection of 
patients at high risk for infection according to 
the criteria for diagnosis of the systemic inflam-
matory response syndrome, followed by cultur-
ing of appropriate specimens and initiation of 
antibiotics. Step two is risk stratification on the 
basis of serum lactate levels, response to fluid 
challenge if the patient has hypotension, or both, 
for appropriate disposition. Patients who are 
stratified for risk on the basis of lactate level and 
a fluid challenge of 30 ml per kilogram have 
more than 19% lower mortality than patients 
who are not stratified in this way.2 Early risk 
stratification also reduces mortality from acute 
cardiopulmonary deterioration, which may occur 
in up to 20% of patients in the early course of 
septic shock.2 These initial steps alone or in 
combination significantly affect mortality.2
The remaining steps of the EGDT protocol 
include effective hemodynamic management of 
preload, afterload, and cardiac contractility and 
assessment of perfusion to balance systemic 
oxygen delivery with demands by measurement 
of Scvo2 and central venous pressure. Early place-
ment of a central venous catheter has been associ-
ated with improved outcomes.2 A low Scvo2 on 
admission to the ICU is associated with mortal-
ity that is at least 10% higher than that with a 
normal Scvo2.
3 Normalization of Scvo2 in acute 
lung injury is associated with decreased duration 
of mechanical ventilation and 15% lower mor-
tality.4 If the Scvo2 is low and the partial pressure 
of arterial oxygen (Pao2) is normal, effective hemo-
dynamic support begins with transfusion of one 
unit of packed red cells to attain a hemoglobin 
level above 10 g per deciliter. Although the hemo-
globin target in this hemodynamic phenotype 
(low Scvo2 and increased lactate level) is not 
known, transfusion has not been associated with 
increased complications and may decrease the 
risk of death.5,6 After correction of arterial oxygen 
content with transfusion, the remaining variable 
that has to be addressed to correct oxygen deliv-
ery is decreased cardiac output (myocardial sup-
pression, which can occur in up to 15% of pa-
tients). Inotropic agents, such as dobutamine, 
are included in the EGDT algorithm to increase 
cardiac output.2
After the original EGDT trial was performed 
and the Surviving Sepsis Campaign was initiat-
ed, the standard of care changed, and mortality 
from sepsis has decreased over the past decade.2 
A recent meta-analysis of three trials (Protocolized 
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Resuscitation in Sepsis Meta-Analysis [PRISM]) 
concluded that there was no mortality benefit 
of protocolized care for sepsis.7 However, the 
PRISM trials provided steps one and two of the 
EGDT protocol as usual care for all treatment 
groups before randomization, and the care was 
unblinded. As a result, many of the patients had 
reached normal Scvo2 and central venous pres-
sure values by the time of randomization and 
also had a lower baseline illness severity, as evi-
denced by the fact that mechanical ventilation 
rates were lower than those in the original EGDT 
trial. These patients had little or no chance to 
benefit from the later steps in the EGDT algo-
rithm that targeted Scvo2-guided effective hemo-
dynamic management. In addition, ICU admis-
sion in these three trials occurred within 2 to 
3 hours after presentation, as compared with 
6 to 8 hours in the original EGDT study. Al-
though early admission to the ICU is a worth-
while goal, it is not a universal reality; thus, the 
results are not generalizable.
The results of the PRISM trials confirm that 
early intervention strategies, including early de-
tection of sepsis, risk stratification, early admin-
istration of antibiotics, and appropriate f luid 
resuscitation, improve the outcomes in patients 
with severe sepsis and septic shock. All these 
steps were components of the original EGDT 
protocol and led to historically low mortality 
rates in both the control groups and the inter-
vention groups in the PRISM studies.2 However, 
because of the limitations of the PRISM trials 
with respect to the patient populations and trial 
methods, the potential benefit of the EGDT steps 
that involved effective hemodynamic manage-
ment was diminished, which increased the prob-
ability of equivalency among the treatment groups.2
In the case of Ms. Jones, I would continue 
monitoring her condition by serial measurements 
of central venous pressure, Scvo2, and lactate 
levels and following the EGDT protocol. EGDT 
is more effective than usual care across a broad-
er range of hemodynamic phenotypes, including 
in patients receiving mechanical ventilation. 
This strategy maximizes her chances of survival 
from septic shock.
Disclosure forms provided by the author are available at 
NEJM.org.
From the Department of Emergency Medicine, Henry Ford Hos-
pital, Detroit. 
Op tion 2
Monitor the Patient  
and Administer Treatment  
on the Basis of Clinical Signs
Mitchell M. Levy, M.D.
Ms. Jones has been admitted to the ICU with 
septic shock and is receiving vasopressors; she 
has received 30 ml per kilogram of fluid resus-
citation but continues to have hypotension and 
oliguria. Her treatment should include continu-
ation of intravenous antibiotics and vasopres-
sors, together with further volume resuscitation 
guided by lactate levels and blood pressure, and 
should not include serial measurement of central 
venous pressure or Scvo2. I would not administer 
blood transfusions or inotropic agents on the 
basis of prespecified target values.
Resuscitation targets and goals have been de-
bated extensively among critical care specialists. 
In 2001, a trial performed by Rivers et al.1 pro-
vided clinicians with practical, evidence-based 
targets for resuscitation with the EGDT algo-
rithm, which was aimed at reducing mortality 
among patients as it had in the trial. Given the 
dearth of previously proven resuscitation targets, 
the field moved quickly to adopt EGDT, including 
its incorporation into international guidelines. 
For the next 13 years, the study by Rivers et al. 
redefined the resuscitation of critically ill pa-
tients and established the importance of early, 
aggressive fluid intervention for resuscitation of 
patients with septic shock.
However, the Protocolized Care for Early Sep-
tic Shock (ProCESS),8 Protocolised Management 
in Sepsis (ProMISE),9 and Australasian Resuscita-
tion in Sepsis Evaluation (ARISE)10 trials, as well 
as PRISM,7 which was the patient-level meta-
analysis of those three trials, failed to confirm 
the survival advantage of protocolized targets for 
central venous pressure, Scvo2, and hemoglobin in 
sepsis resuscitation. It is important for clinicians 
to realize that even in the ARISE and ProCESS 
trials, after patients received 30 ml per kilogram 
of fluid resuscitation, the mean Scvo2 before ran-
domization was already more than 70%, which 
was the target in the intervention group in the 
study by Rivers et al. However, with the publica-
tion of the PRISM patient-level meta-analysis, 
The New England Journal of Medicine 
Downloaded from nejm.org at HENRY FORD HOSPITAL on December 9, 2019. For personal use only. No other uses without permission. 
 Copyright © 2017 Massachusetts Medical Society. All rights reserved. 
Clinical Decisions
n engl j med 376;23 nejm.org June 8, 2017 2285
the evidence puts to rest the need for mandated 
placement of a central venous catheter in every 
patient with severe sepsis and septic shock for 
the purpose of serial monitoring of central ve-
nous pressure or Scvo2 to guide resuscitation.
The challenge for practicing clinicians is how 
to understand “usual care” in the settings of these 
large randomized, controlled trials. The trial by 
Rivers et al. and subsequent studies heightened 
awareness of sepsis as an urgent medical condi-
tion, which over the ensuing years has led to an 
unmistakable change in the standard of care for 
critically ill patients with sepsis. Regardless of 
attitudes about the validity of the specific details 
of the EGDT protocol, clinicians have come to 
embrace the need for rapid identification of sepsis 
and early treatment with antibiotics and fluids.
So the question remains, what can clinicians 
use at the bedside to guide resuscitation? After 
administration of the minimal suggested fluid 
volume (30 ml per kilogram), the proper balance 
between the use of additional fluids and the use 
of vasopressors alone to maintain a mean arte-
rial pressure of greater than 65 mm Hg remains 
uncertain. In the case of Ms. Jones, I would guide 
resuscitation by serial lactate measurement. Two 
separate randomized, controlled trials have shown 
the benefit of lactate-guided therapy in resusci-
tation.11,12 Measurement of urine output may be 
helpful, but in a patient with preexisting hyper-
tension who may have unrecognized kidney dis-
ease, restoration of adequate urine output may be 
delayed. Normalization of the lactate level may be 
the most practical target in deciding whether 
further fluid administration is needed. Several 
clinical trials are now under way that will evalu-
ate restricted volume resuscitation in comparison 
with a more liberal approach. For now, the pre-
cise total amount of fluids administered to a 
patient with septic shock can be guided by tar-
geting a mean arterial pressure of 65 mm Hg 
with fluids and vasopressors while normalizing 
the lactate level.
In conclusion, I would treat Ms. Jones accord-
ing to updated guidelines13 for patients with 
septic shock, which incorporate findings from 
the trials outlined above. Antibiotics, vasopres-
sors, and fluids remain the cornerstones of ther-
apy; serial measurement of central venous pres-
sure and Scvo2 along with blood transfusions and 
administration of inotropic agents is not likely 
to improve her outcome.
Disclosure forms provided by the author are available at 
NEJM.org.
From the Alpert Medical School at Brown University and Rhode 
Island Hospital — both in Providence. 
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